Compare FC & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FC | VYGR |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.6M | 203.6M |
| IPO Year | 1994 | 2015 |
| Metric | FC | VYGR |
|---|---|---|
| Price | $19.02 | $3.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $26.00 | $16.50 |
| AVG Volume (30 Days) | 56.3K | ★ 407.4K |
| Earning Date | 04-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $267,067,000.00 | $10,135,000.00 |
| Revenue This Year | $3.15 | $34.04 |
| Revenue Next Year | $4.04 | $7.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.16 | $2.94 |
| 52 Week High | $26.81 | $5.55 |
| Indicator | FC | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 33.50 | 50.66 |
| Support Level | $15.87 | $3.33 |
| Resistance Level | $21.15 | $3.56 |
| Average True Range (ATR) | 0.78 | 0.15 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 21.48 | 44.16 |
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.